Physician profile
Thomas Kepczyk
NPI 1629062344
$12,568.06
in general payments reported to CMS, 2019-2025
49 companies · $2,200 in 2025
The $2,200 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,737 · 2020: $929 · 2021: $1,535 · 2022: $1,759 · 2023: $1,931 · 2024: $2,477 · 2025: $2,200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,596 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,596.36 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,697.13 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,394.65 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $878.48 | 2019-2025 | Stelara, Tremfya, Simponi |
| Qol Medical, LLC | $693.78 | 2019-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $479.44 | 2020-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $446.81 | 2019-2025 | Eohilia |
| Ferring Pharmaceuticals INC. | $380.25 | 2019-2025 | Rebyota, Clenpiq |
| Pfizer INC. | $371.88 | 2019-2025 | |
| Gilead Sciences, INC. | $365.51 | 2019-2024 | Livdelzi |
| Lilly USA, LLC | $293.39 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $265.92 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $237.27 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $235.24 | 2024-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $227.32 | 2021-2023 | |
| Celgene Corporation | $226.54 | 2021-2024 | Zeposia |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $222.99 | 2025 | Fibroscan |
| Genzyme Corporation | $196.67 | 2022-2025 | |
| Daiichi Sankyo INC. | $191.51 | 2019-2024 | Injectafer |
| Ucb, INC. | $177.30 | 2019-2020 | |
| Ardelyx, INC. | $164.48 | 2022-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $136.25 | 2024-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $129.01 | 2019-2024 | Dificid |
| Fujifilm Healthcare Americas Corporation | $124.73 | 2024 | Fujifilm |
| Ironwood Pharmaceuticals, INC | $121.20 | 2019-2024 | Linzess |
| Aimmune Therapeutics, INC. | $100.10 | 2024-2025 | Zenpep |
| Amgen INC. | $95.60 | 2021-2023 | Amjevita, Avsola |
| Evoke Pharma, INC. | $91.09 | 2022-2024 | Gimoti |
| Redhill Biopharma INC. | $83.83 | 2020-2022 | |
| Madrigal Pharmaceuticals | $81.22 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $62.70 | 2020-2024 | Sutab, Suflave |
| Romark Laboratories, Lc | $54.93 | 2019-2020 | |
| Celltrion USA INC. | $48.83 | 2025 | Vegzelma |
| Amag Pharmaceuticals, INC. | $47.84 | 2021-2022 | |
| Organon LLC | $36.93 | 2022-2023 | Renflexis |
| Johnson & Johnson Health Care Systems INC. | $31.89 | 2022-2023 | Stelara |
| Fresenius Kabi USA, LLC | $31.76 | 2024 | Idacio |
| Pharmacosmos Therapeutics INC. | $31.06 | 2020-2023 | Monoferric |
| Orphalan INC | $21.77 | 2025 | Cuvrior |
| Novo Nordisk INC | $20.21 | 2025 | Wegovy |
| Shire North American Group INC | $18.51 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.12 | 2025 | Suflave |
| Vivus LLC | $14.88 | 2025 | Pancreaze |
| Alfasigma USA, INC. | $13.38 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $6.66 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kepczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.